Influenza Vaccine Dose and Dementia Outcomes - Summary - MDSpire
From the Journals

Influenza Vaccine Dose and Dementia Outcomes

US claims data compare high- vs standard-dose formulations in patients aged 65 years or more over 3 years of follow-up

Share

A study found that high-dose influenza vaccination in patients aged 65 and older was associated with a reduced risk of developing Alzheimer dementia within 25 months compared to standard-dose vaccination. Using a large database, researchers observed 185,183 high-dose and 53,918 standard-dose trials, adjusting for confounding factors. Results indicated a lower cumulative risk of Alzheimer dementia with high-dose vaccine, particularly among women. However, limitations such as short follow-up and potential misclassification were noted, leaving underlying mechanisms unclear.

Original Source(s)

Influenza Vaccine Dose and Dementia Outcomes

  • by Kathryn Wighton

  • April 10, 2026

Related Content

Midlife Vitamin D Linked to Lower Tau

Higher vitamin D levels in early midlife were tied to lower tau burden on later brain imaging, while no association was seen with amyloid.

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.